Matt Lallas
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1700170180
Payments from drug & device makers
Across 625 payments — averaging $542.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$140K
- Jazz Pharmaceuticals Inc.$71K
- H. Lundbeck A S$43K
- Eisai Inc.$39K
- Immedica Pharma US, Inc.$35K
- UCB, Inc.$4K
- plus $7K from 25 others
Across 4 payments — averaging $9747.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurelis, Inc.$39K
What the payments were for
- Consulting fees$2,6403%
- Speaking & faculty fees$69,87979%
- Travel & lodging$100%
- Food & beverage$15,70118%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 121 | $140,039 |
| Jazz Pharmaceuticals Inc. | 103 | $70,651 |
| H. Lundbeck A S | 6 | $43,197 |
| Eisai Inc. | 24 | $39,092 |
| Immedica Pharma US, Inc. | 25 | $34,945 |
| UCB, Inc. | 110 | $4,408 |
| Zogenix Inc. | 7 | $1,564 |
| Aquestive Therapeutics, Inc. | 36 | $817 |
| Livanova USA, Inc. | 24 | $731 |
| Greenwich Biosciences, Inc. | 24 | $547 |
| Neuropace, Inc. | 5 | $486 |
| SK Life Science, Inc. | 21 | $437 |
| Sumitomo Pharma America, Inc. | 18 | $426 |
| Sunovion Pharmaceuticals Inc. | 18 | $365 |
| Ironshore Pharmaceuticals Inc. | 17 | $243 |
| Corium, LLC | 14 | $237 |
| Supernus Pharmaceuticals, Inc. | 13 | $198 |
| Biocodex, Inc. | 6 | $171 |
| Biogen | 6 | $131 |
| Catalyst Pharmaceuticals, Inc. | 6 | $112 |
| Aprecia Pharmaceuticals, LLC | 6 | $107 |
| Aucta Pharmaceuticals, Inc. | 3 | $77 |
| Acadia Pharmaceuticals Inc | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $48 |
| Neuroone Medical Technologies Corporation | 1 | $41 |
| Novartis | 2 | $27 |
| AstraZeneca | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| NS Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$69,258
- Fintepla$1,993
- RNS Neurostimulator Kit$440
- Briviact$125
How this compares
$339,235 in reported general payments places this provider in the 90th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Miami
- Ian MillerMiami$1.1M
- Migvis MonduyMiami$455K
- Paula SchleiferMiami$394K
- Anuj JayakarMiami$361K
- Trevor ResnickMiami$313K
- Nelson SanchezMiami$255K
- Elza VasconcellosMiami$245K
- Marytery FajardoMiami$119K
- Fernando GalanMiami$103K
- Wilson Heredia NunezMiami$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.